ACTIVE

PHENIX PROPERTY

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

691,5 k €

+4490.4% YoY

Equity

934,1 k €

+44.5% YoY

What does PHENIX PROPERTY do?

PHENIX PROPERTY is a Public limited company incorporated in 1973. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Hoogstraten.

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0413.676.987

Incorporation

30/10/1973

Legal form

Public limited company

Registered office

Sint Lenaartseweg 48
2320 Hoogstraten · FlandreSee on map

Contributed capital

199 250,00 €

Latest accounts

31/12/2025

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 24421Aluminium production

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Revenue	–		–		–		–		–		–		–		–		–		–		–		–		–		–		–		–		–		11,8 k €	-65.6%	34,3 k €	+148%	13,8 k €
EBITDA	872,2 k €	+5654%	-15,7 k €	-157%	-6,1 k €	-68.2%	-3,6 k €	+5.7%	-3,9 k €	-9.7%	-3,5 k €	+32.8%	-5,2 k €	-85.3%	-2,8 k €	+42.8%	-4,9 k €	-116%	30,2 k €	+174%	-40,8 k €	-175%	-14,8 k €	+53.4%	-31,9 k €	-77.5%	-18 k €	-138%	-7,6 k €	-102%	-3,7 k €	-33.3%	-2,8 k €	+74.7%	-11,1 k €	-299%	-2,8 k €	-118%	15 k €
Operating result	872,2 k €	+5654%	-15,7 k €	-157%	-6,1 k €	-68.2%	-3,6 k €	+5.7%	-3,9 k €	-9.7%	-3,5 k €	+32.8%	-5,2 k €	-85.3%	-2,8 k €	+42.8%	-4,9 k €	-116%	30,2 k €	+174%	-40,8 k €	-175%	-14,8 k €	+53.4%	-31,9 k €	-77.5%	-18 k €	-138%	-7,6 k €	-102%	-3,7 k €	-33.3%	-2,8 k €	+74.7%	-11,1 k €	-299%	-2,8 k €	-118%	15 k €
Net result	691,5 k €	+4490%	-15,8 k €	-156%	-6,2 k €	-62.8%	-3,8 k €	+6.7%	-4 k €	-38.5%	-2,9 k €	+37.0%	-4,6 k €	+1.2%	-4,7 k €	+5.2%	-5 k €	-111%	46,2 k €	+94.8%	23,7 k €	+135%	10,1 k €	+132%	-31,6 k €	-1423%	2,4 k €	-96.5%	67,8 k €	+1843%	-3,9 k €	-38.7%	-2,8 k €	-188%	3,2 k €	-89.7%	30,9 k €	+164%	-47,9 k €
Balance sheet
Equity	934,1 k €	+44.5%	646,7 k €	-2.4%	662,4 k €	-0.9%	668,6 k €	-0.6%	672,4 k €	-0.6%	676,4 k €	-0.4%	679,3 k €	-0.7%	684 k €	-0.7%	688,7 k €	-0.7%	693,6 k €	+7.1%	647,4 k €	+3.8%	623,7 k €	+1.6%	613,6 k €	-4.9%	645,2 k €	+0.4%	642,8 k €	+2.0%	630 k €	-0.6%	633,9 k €	-0.4%	636,7 k €	-39.6%	1,1 M €	-2.9%	1,1 M €
Total assets	1,1 M €	+70.8%	660,6 k €	-0.6%	664,8 k €	-1.0%	671,4 k €	-0.5%	674,9 k €	-2.6%	692,8 k €	-0.4%	695,2 k €	-0.5%	698,9 k €	-0.6%	703,4 k €	-0.7%	708,4 k €	+1.5%	697,8 k €	+6.4%	655,8 k €	+1.3%	647,2 k €	-4.1%	674,8 k €	-5.1%	711,3 k €	+7.9%	659,1 k €	-1.7%	670,8 k €	-37.5%	1,1 M €	-10.7%	1,2 M €	-0.5%	1,2 M €
Cash	150 k €		–		–		–		528,9 €		–		–		–		833,2 €	-23.0%	1,1 k €		–		–		–		6 k €	+8996%	65,8 €	-69.9%	218,4 €	-15.7%	259 €	-22.0%	332,1 €	+323%	78,4 €	-99.8%	36,7 k €
Debts	194,3 k €	+1299%	13,9 k €	+486%	2,4 k €	-17.4%	2,9 k €	+13.8%	2,5 k €	-84.5%	16,3 k €	+2.6%	15,9 k €	+6.4%	14,9 k €	+1.5%	14,7 k €	-0.7%	14,8 k €	-70.6%	50,3 k €	+56.8%	32,1 k €	-4.5%	33,6 k €	+13.6%	29,6 k €	-56.7%	68,5 k €	+136%	29 k €	-21.2%	36,9 k €	-91.6%	437,2 k €	+198%	146,6 k €	+21.9%	120,3 k €

Estimate

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 19 ended

Active mandates

VOXDALE

Director · since 19 décembre 2023 · 0435.552.467

Represented by René BEYERS

Active

Ended mandates

KELA - Kempisch Laboratorium - Kela Laboratoria

Managing director · since 20 juin 2023 · until 19 décembre 2023 · 0403.835.645

Represented by René Beyers

Ended

Philomena VAN PELT

Director · since 20 juin 2023 · until 19 décembre 2023

Ended

Renatus BEYERS

Director · since 20 juin 2023 · until 19 décembre 2023

Ended

KELA - Kempisch Laboratorium - Kela Laboratoria

Managing director · since 14 novembre 2017 · until 09 mai 2023 · 0403.835.645

Represented by René BEYERS

Ended

At this address

Other companies at this address

Company	CBE no.
KELA - Kempisch Laboratorium - Kela Laboratoria● Active	0403.835.645
KELA VETERINARIA● Active	0412.402.527
Medicem● Active	0418.885.986
VOXDALE● Active	0435.552.467

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	01/07/2026	30/06/2025	03/07/2024	19/07/2023	20/07/2022	19/07/2021
General meeting	02/06/2026	03/06/2025	04/06/2024	20/06/2023	24/06/2022	25/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	02/06/2026	01/07/2026	Dutch	PDF
Full model	31/12/2024	03/06/2025	30/06/2025	Dutch	PDF
Full model	31/12/2023	04/06/2024	03/07/2024	Dutch	PDF
Full model	31/12/2022	20/06/2023	19/07/2023	Dutch	PDF
Full model	31/12/2021	24/06/2022	20/07/2022	Dutch	PDF
Full model	31/12/2020	25/06/2021	19/07/2021	Dutch	PDF
Full model	31/12/2019	29/06/2020	03/07/2020	Dutch	PDF
Full model	31/12/2018	14/05/2019	15/07/2019	Dutch	PDF
Full model	31/12/2017	08/05/2018	08/06/2018	Dutch	PDF
Full model	31/12/2016	09/05/2017	01/06/2017	Dutch	PDF
Full model	31/12/2015	17/05/2016	27/06/2016	Dutch	PDF
Full model	31/12/2014	12/05/2015	24/06/2015	Dutch	PDF
Full model	31/07/2013	17/12/2013	14/01/2014	Dutch	PDF
Full model	31/07/2012	18/12/2012	08/01/2013	Dutch	PDF
Full model	31/07/2011	20/12/2011	22/02/2012	Dutch	PDF
Full model	31/07/2010	21/12/2010	07/01/2011	Dutch	PDF
Full model	31/07/2009	15/12/2009	02/02/2010	Dutch	PDF
Full model	31/12/2008	19/05/2009	23/06/2009	Dutch	PDF
Full model	31/12/2007	20/05/2008	11/06/2008	Dutch	PDF
Full model	31/12/2006	29/05/2007	21/06/2007	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 1 active · 19 ended

Active mandates

VOXDALE

Director · since 19 décembre 2023 · 0435.552.467

Represented by René BEYERS

Active

Ended mandates

KELA - Kempisch Laboratorium - Kela Laboratoria

Managing director · since 20 juin 2023 · until 19 décembre 2023 · 0403.835.645

Represented by René Beyers

Ended

Philomena VAN PELT

Director · since 20 juin 2023 · until 19 décembre 2023

Ended

Renatus BEYERS

Director · since 20 juin 2023 · until 19 décembre 2023

Ended

KELA - Kempisch Laboratorium - Kela Laboratoria

Managing director · since 14 novembre 2017 · until 09 mai 2023 · 0403.835.645

Represented by René BEYERS

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates12/01/2024
DIVERSEN - DOEL - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
PDF
Mandates05/01/2024
ONTSLAGEN - BENOEMINGEN
PDF
Mandates27/04/2021
ONTSLAGEN - BENOEMINGEN
PDF
Mandates20/12/2017
ONTSLAGEN - BENOEMINGEN
PDF
Mandates14/06/2017
ONTSLAGEN - BENOEMINGEN
PDF
Capital / shares06/07/2015
KAPITAAL - AANDELEN
PDF
Other30/07/2014
ALGEMENE VERGADERING - BOEKJAAR
PDF
Mandates22/01/2014
ONTSLAGEN - BENOEMINGEN
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025691,5 k €↑
2024
Annual accounts 2024-15,8 k €↓
2023
Annual accounts 2023-6,2 k €↓
2022
Annual accounts 2022-3,8 k €↑
2021
Annual accounts 2021-4 k €↓
2020
Annual accounts 2020-2,9 k €↑
2019
Annual accounts 2019-4,6 k €↑
2018
Annual accounts 2018-4,7 k €↑
2017
Annual accounts 2017-5 k €↓
2016
Annual accounts 201646,2 k €↑
2015
Annual accounts 201523,7 k €↑
2014
Annual accounts 201410,1 k €↑
2013
Annual accounts 2013-31,6 k €↓
2012
Annual accounts 20122,4 k €↓
2011
Annual accounts 201167,8 k €↑
2010
Annual accounts 2010-3,9 k €↓
2009
Annual accounts 2009-2,8 k €↓
2009
Name changePHENIX PROPERTY
2008
Annual accounts 20083,2 k €↓
2007
Annual accounts 200730,9 k €↑
2006
Annual accounts 2006-47,9 k €
2006
Name changePHENIX PHARMACEUTICALS
30/10/1973
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

PHENIX PROPERTY

Overview

What does PHENIX PROPERTY do?

Trend over 20 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline